Clinical trials: Adenocarcinoma of the Prostate
Prostate Cancer
Pomegranate Juice in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Pomegranate juice may contain substances that decrease or slow the rise of prostate-specific antigen (PSA) levels and may be effective in delaying or preventing recurrent prostate cancer.
- Trial name
- NCT00060086
- Testing
- pomegranate juice
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Carcinoma, Renal Cell, Prostatic Neoplasms
Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
The purpose of this study is to evaluate the safety and tolerability of extended treatment with FK228 in patients with metastatic renal cell carcinoma or hormone refractory prostate cancer who have at least demonstrated stable…
- Trial name
- NCT00106301
- Testing
- FK228 (romidepsin)
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Celgene
Prostate Cancer, Prostate Adenocarcinoma
Multi-modality Imaging (PCa) Using Sodium MRI and PSMA PET in Men Pre-prostatectomy
The study is a non-randomized, prospective trial of men scheduled for radical prostatectomy for treatment of prostate cancer as standard of care and will undergo a series of pre-operative multi-modality imaging studies.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm
- Trial name
- IGPC-5 (NCT04053842)
- Testing
- PET Scan, [18F]PSMA-1007 Injection, Sodium MRI
- Where
- Canada
- Volunteers
- 16 people
- Sponsor
- Glenn Bauman
Prostate Cancer, Adenocarcinoma of the Prostate
Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy
The main purpose of this trial is to collect information and to evaluate the effects, good or bad, the combination of docetaxel and bevacizumab has on patients with high risk prostate cancer that are undergoing radical…
- Trial name
- NCT00321646
- Testing
- Bevacizumab, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Mary-Ellen Taplin, MD
Prostate Cancer
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have…
- Trial name
- NCT00010127
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Duke University
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer (Adenocarcinoma)
Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer
This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer.
- Trial name
- NCT06838520
- Testing
- Bone health assessment
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Genitourinary Cancers
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
SOGUG-PRINCIS is a retrospective (regarding patient inclusion) and prospective follow-up, epidemiological, non-interventional, non-blinded, non-randomized, multicenter, national observational study with drugs.
- Trial name
- SOGUG-PRINCIS (NCT06724159)
- Testing
- darolutamide, Nivolumab monotherapy, enfortumab vedotin
- Where
- 84 sites in Spain
- Volunteers
- 500 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
This clinical trial studies stereotactic body radiation therapy in treating patients with high-risk prostate cancer that has not spread to nearby lymph nodes or to other parts of the body.
- Trial name
- NCT02296229
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Cancer
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have recurrent prostate cancer.
- Trial name
- NCT00030602
- Testing
- PSA prostate cancer vaccine, incomplete Freund's adjuvant
- Sponsor
- University of Maryland, Baltimore
Prostate Cancer
Doxercalciferol Before Surgery in Treating Localized Prostate Cancer
RATIONALE: Doxercalciferol may be an effective way to treat localized prostate cancer before surgery. PURPOSE: Randomized phase II trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who…
- Trial name
- NCT00022412
- Testing
- doxercalciferol, conventional surgery
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Malignant Neoplasms of Male Genital Organs, Prostate Cancer
Neoadjuvant Listeria or Daratumumab in Prostate Cancer
The goal of this clinical research study is to learn about biomarker changes in patients who have primary prostate cancer after receiving Darzalex (daratumumab) and then have a prostatectomy (the surgical removal of the prostate)…
- Trial name
- NCT03035357
- Testing
- Daratumumab
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Prostate Adenocarcinoma
Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors
The goal of this clinical research study is to evaluate the safety of PEG-BCT- 100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate…
- Trial name
- NCT02285101
- Testing
- PEG-BCT-100
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Bio-Cancer Treatment International Limited
Prostate Cancer
Paclitaxel and Carboplatin in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00049257
- Testing
- carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma
Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
This example Phase 1 study is designed to evaluate the safety, tolerability, feasibility, and preliminary anti-tumor activity of ETB-DualNK-01, an allogeneic dual-target PSMA/PSCA CAR-NK cell therapy, in adults with metastatic…
- Conditions
- Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
- Trial name
- DUAL-NK-PC (NCT07641049)
- Testing
- ETB-DualNK-01, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
- Trial name
- NCT04126070
- Testing
- Androgen Deprivation Therapy, Nivolumab, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Xiao X. Wei, MD
Breast Carcinoma, Colon Carcinoma
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
This phase I trial studies a new imaging technique called FAPi PET/CT to determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulate in normal and cancer tissues in patients with non-prostate cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma
- Trial name
- NCT04147494
- Testing
- Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Prostate Adenocarcinoma
Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma
- Trial name
- NCT01709253
- Testing
- proton beam therapy
- Where
- South Korea
- Volunteers
- 117 people
- Sponsor
- National Cancer Center, Korea
Prostate Cancer
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known whether radiation therapy to the prostate and pelvis is more effective than radiation therapy to the prostate alone in treating…
- Trial name
- NCT00003607
- Testing
- radiation therapy
- Where
- 23 sites in France
- Volunteers
- 450 people
- Sponsor
- UNICANCER
Advanced Prostate Adenocarcinoma
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
A study to assess safety and tolerability of AZD2171 after multiple doses in patients with advanced prostate cancer.
- Trial name
- AZD2171IL/0003 (NCT00502164)
- Testing
- AZD2171
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca